JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin receptor to treat severe asthma, chronic rhinosinusinitis with nasal polyps and COPD, the analyst tells investors in a research note. The firm sees verekitug as the sole driver for shares over the mid to long term as the clinical profile matures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UPB:
- Opening Day: Polyrizon, Gelteq debut in quiet IPO week
- Opening Day: Ingram Micro returns to trading in busy week
- Opening Day: Self-driving startup Pony.ai files for U.S. IPO
- Opening Day: Another trio of biotech IPOs make Friday debut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
